Journal of the Korea Academia-Industrial cooperation Society (한국산학기술학회논문지)

The Korea Academia-Industrial cooperation Society (한국산학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Development of Technology Portfolio Analysis method for Technology-outsourcing of Pharmaceutical cooperations

제약기업의 기술 아웃소싱을 위한 기술포트폴리오 분석 방법 개발

  • Hong, Sukchul (Department of Management of Technology, Sungkyunkwan University)
  • 홍석철 (성균관대학교 기술경영학과)
  • Received : 2013.10.04
  • Accepted : 2013.11.07
  • Published : 2013.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study proposes a technology portfolio analysis method for technology outsourcing of pharmaceutical cooperations by applying the concepts of 'Pipeline Soundness' and 'Patent Validity'. This study also applied the developed portfolio analysis method to a 'real world case' of Amgen's acquisition of Onyx Pharmaceuticals to prove the applicability of the method to the real world cases and investigated the validity of the acquisition affair between the two companies. The results of portfolio analysis showed that Amgen's technology portfolio will be improved by acquiring Onyx Pharmaceuticals especially in cancer field which is their main field. So we concluded that Amgen's choice of Onyx pharmaceuticals as a source of technology outsourcing was reasonable. We think that the technology portfolio analysis method developed by this study will be a valuable tool for pharmaceutical cooperations for investigating their current technology status and selecting target companies for technology outsourcing.

본 논문에서는 '파이프라인 건전도(Pipeline Soundness)와 특허유효성(Patent Validity)개념을 적용하여 제약기업이 적합한 기술 아웃소싱 대상기업을 선정하기 위한 기술 포트폴리오 방법을 제시하고자 한다. 또한 이를 최근 발표한 Amgen의 Onyx Pharmaceuticals 인수사례에 적용하여 개발된 포트폴리오 분석방법의 실제 적용 가능성을 검토하고 사례기업의 기술아웃소싱 타당성을 분석하기로 한다. 본 연구를 통해 제시된 기술포트폴리오의 사례 적용 분석 결과 Amgen은 주력분야인 Cancer 분야의 특허유효성 개선이 시급한 것으로 분석되었으며 Onyx Pharmaceuticals의 인수를 통해 Cancer 분야의 기술포트폴리오를 안정적인 영역에 도달시킬 것으로 기대된다. Amgen의 실제 Onyx Pharmaceuticals 인수 이유 또한 Cancer 분야의 파이프라인 강화와 의약품 도입이라는 점을 고려할 때 새롭게 개발된 기술포트폴리오 분석방법이 실제사례에 잘 적용됨을 알 수 있었으며, 본 연구를 통해 개발된 기술포트폴리오 분석 방법이 제약기업의 기술현황 파악 및 인수대상기업 선정을 위한 도구로 충분히 활용 가능할 수 있을 것으로 판단된다.

Keywords

References

  1. Munos, B. "Lessons from 60 years of pharmaceutical innovation." Nat. Rev. Drug Discov.. 8, p.959-968, 2009. Available from: http://www.nature.com/nrd/journal/v8/n12/full/nrd2961.html DOI: http://dx.doi.org/10.1038/nrd2961
  2. Chesbrough, H.W. Open innovation: The new imperative for creating and profiting from technology, Boston, Harvard Business School Press, 2003. Available from: http://www.sciencedirect.com/science/article/pii/S0304405X05001807
  3. Mathew J. Higgins, Daniel Rodriguez. The outsourcing of R&D through acquisitions in the pharmaceutical industry. Journal of Financial Economics. 80, p351-383, 2006. Available from: http://www.sciencedirect.com/science/article/pii/S030440 5X05001807 DOI: http://dx.doi.org/10.1016/j.jfineco.2005.04.004
  4. Danzon, P., Epstein, A., Nicholson, S., Mergers and acquisitions in the pharmaceutical and biotech industries. NBER Working Paper Series, Paper 10536.Available from: http:// www.nber.org/papers/w10536
  5. Anthony Breizman, Patrick Thomas. "Using patent citation analysis to target/value M&A candidates.", Research Technology Management, pp.28-36, 2002. Available from: http/www.ngentaconnect.com contentiri/tm/2002 00000045 00000005art00006
  6. Bernd Fabry, Holger Ernst, Jens Langholz, Martin Koster. Patent portfolio analysis as a useful tool for identifying R&D and business opportunities-an empirical application in the nutrition and health industry. World Patent Information. 28. 215-225, 2006. Available from: http://www.sciencedirect.com/science/article/pii/S0172219005001407 DOI: http://dx.doi.org/10.1016/j.wpi.2005.10.004
  7. Chih-Ping Wei, Yu-Syun Jiang, and Chin-Sheng Yang. "Patent analysis for supporting Merger and acquisition(M&A) prediction: A data mining approach", Lecture notes in business information processing. 22. p.187-200, 2009. Available from: http:/link.springer.comchapter10.1007978-3-642-01256-3_16# DOI: http://dx.doi.org/10.1007/978-3-642-01256-3_16
  8. Kriegerm D., Ruback, R.S. Merck & company: evaluating a drug licensing opportunity. Harvard Business School Case #9-201-023. Available from: http:/www.hbs.edu/faculty Pages/ tem.aspx?num=27606
  9. Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie, Charles C. Persinger, Bernard H. Munos, Stacy R. Lindborg, Aaron L. Schacht. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews. 9. 203-214. 2010. Available from: http://www.nature.com/nrd/journal/v9/n3/full/nrd3078.html
  10. Holger Ernst. Patent portfolio for strategic R&D planning. J. Eng. Technol. Manage. 15. 279-308, 1998. Available from: http: // www.sciencedirect.com/ science/article/pii/S0923474898000186 DOI: http://dx.doi.org/10.1016/S0923-4748(98)00018-6
  11. Gudrun Littmann-Hilmer, Michael Kuckartz. SME tailor-designed patent portfolio analysis. World Patent information. 31. 273-277. 2009. Available from: http://www.sciencedirect.com/science/article/pii/S0172219008001762 DOI: http://dx.doi.org/10.1016/j.wpi.2008.12.003
  12. Anne Marie Clark, Heidi Berven. The face of the patent is not the "Whole Story" : determining the effective life of a pharmaceutical patent in the United States. World Patent Information. 26. 283-295. 2004. Available from: http://www.sciencedirect.com/science/article/pii/S017221 9004000675 DOI: http://dx.doi.org/10.1016/j.wpi.2004.04.010
  13. Henry G. Grabowski. John M. Vernon. Effective patent life in pharmaceuticals. Int. J. Technology Management. 19. 98-120. 2000. Available from: http://inderscience.metapress.com/content/fg1begfe6rxh8vx7/ https://doi.org/10.1504/IJTM.2000.002803
  14. John A. Pearce II. How companies can preserve market dominance after patents expire. Long Range Planning. 39. 71-87. 2006. Available from: http://www.sciencedirect.com/science/article/pii/S0024630105000592 DOI: http://dx.doi.org/10.1016/j.lrp.2005.04.006
  15. Ronald J. Vogel. Pharmaceutical Patents and Price Controls, Clinical Therapeutics, 24(7), 1204-1222, 2002. Available from: http://www.sciencedirect.com/science/article/pii/S0024630105000592 DOI: http://dx.doi.org/10.1016/S0149-2918(02)80031-5